Glenmark Pharmaceuticals Limited (GLENMARK) Gross Profit 2022–2026

Name: Glenmark Pharmaceuticals Limited (GLENMARK) gross profit history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Glenmark Pharmaceuticals Limited annual gross profit for fiscal 2026 was ₹116.0 billion, an increase of 38.3% from ₹83.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLENMARK Annual Gross Profit

Gross Profit (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Gross Profit	₹116.0B	₹83.9B	₹67.6B	₹68.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLENMARK Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Gross Profit	₹26.9B	₹25.9B	₹25.9B	₹47.4B	₹20.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

DRREDDY Gross Profit — Dr. Reddy's Laboratories Limited
LUPIN Gross Profit — Lupin Limited
MANKIND Gross Profit — Mankind Pharma Limited
4506 Gross Profit — Sumitomo Pharma Co., Ltd.
ALKEM Gross Profit — Alkem Laboratories Limited
ABBOTINDIA Gross Profit — Abbott India Limited

More GLENMARK metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All GLENMARK financial statements → Interactive GLENMARK charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.